EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), featured a series of presentations of new "real-world" data on transcatheter aortic valve systems during a May 22 Late-Breaking Trial session, including new outcomes with Edwards Lifesciences Corp.'s Sapien 3, Abbott Laboratories Inc.'s Portico, and Medtronic PLC's CoreValve Evolut R.
Edwards' Sapien 3 transcatheter aortic valve is performing as well in the real-world intermediate surgical-risk patients as it did...